alexa Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study.
Nursing

Nursing

Journal of Patient Care

Author(s): Cabibbo G, Maida M, Genco C, Parisi P, Peralta M,

Abstract Share this page

Abstract AIM: To investigate the clinical course of untreatable hepatocellular carcinoma (HCC) identified at any stage and to identify factors associated with mortality. METHODS: From January 1999 to December 2010, 320 out of 825 consecutive patients with a diagnosis of HCC and not appropriate for curative or palliative treatments were followed and managed with supportive therapy. Cirrhosis was diagnosed by histological or clinical features and liver function was evaluated according to Child-Pugh score. The diagnosis of HCC was performed by Ultra-Sound guided biopsy or by multiphasic contrast-enhanced computed tomography or gadolinium-enhanced magnetic resonance imaging. Data were collected for each patient including all clinical, laboratory and imaging variables necessary for the outcome prediction staging systems considered. HCC staging was performed according Barcelona Clinic Liver Cancer (BCLC) and Cancer of the Liver Italian Program scores. Follow-up time was defined as the number of months from the diagnosis of HCC to death. Prognostic baseline variables were analyzed by multivariate Cox analysis to identify the independent predictors of survival. RESULTS: Seventy-five per cent of patients had hepatitis C. Ascites was present in 169 patients (53\%), while hepatic encephalopathy was present in 49 patients (15\%). The Child-Pugh score was class A in 105 patients (33\%), class B in 142 patients (44\%), and class C in 73 patients (23\%). One hundred patients (31\%) had macroscopic vascular invasion and/or extra-hepatic spread of the tumor. A single lesion > 10 cm was observed in 34 patients (11\%), while multinodular HCC was present in 189 patients (59\%). Thirty nine patients (12\%) were BCLC early (A) stage, 55 (17\%) were BCLC intermediate (B) stage, 124 (39\%) were BCLC advanced (C) stage, and 102 (32\%) were end-stage BCLC (D). At the time of this analysis (July 2011), 28 (9\%) patients were still alive. Six (2\%) patients who were lost during follow-up were censored at the last visit. The overall median survival was 6.8 mo, and the 1-year survival was 32\%. The 1-year survival according to BCLC classes was 100\%, 79\%, 12\% and 0\%, for BCLC A, B, C and D, respectively. There was a significant difference in survival between each BCLC class. The median survival of patients of BCLC stages A, B, C and D was 33, 17.4, 6.9, and 1.8 mo, respectively (P < 0.05 for comparison between stages). The median survival of Child-Pugh A, B and C classes were 9.8 mo (range 6.4-13), 6.1 (range 4.9-7.3), and 3.7 (range 1.5-6), respectively (P < 0.05 for comparison between stages). By univariate analysis, the variables significantly associated to an increased liklihood of mortality were Eastern Cooperative Oncology Group performance status (PS), presence of ascites, low level of albumin, elevated level of bilirubin, international normalized ratio (INR) and Log-[(α fetoprotein (AFP)]. At multivariate analysis, mortality was independently predicted by bad PS (P < 0.0001), high INR values (P = 0.0001) and elevated Log-(AFP) levels (P = 0.009). CONCLUSION: This study confirms the heterogeneous behavior of untreated HCC. BCLC staging remains an important prognostic guide and may be important in decision-making for palliative treatment.
This article was published in World J Hepatol and referenced in Journal of Patient Care

Relevant Expert PPTs

Relevant Speaker PPTs

  • Sundeep Kumar Upadhyaya
    LONG TERM DRUG-FREE CLINICAL-REMISSION IN PATIENTS WITH RA ON cDMARDs
    PPT Version | PDF Version
  • Shi-Zhong Yang
    Fast hydrolysis for determination of lipopeptides on solid surface
    PPT Version | PDF Version
  • Mohammad Othman
    Probiotics for the prevention of preterm labour
    PPT Version | PDF Version
  • Abinaya Vijayan
    Careful Diagnosis and Management of Monochorionic Monoamniotic twins
    PPT Version | PDF Version
  • Rubina Ghani
    STD pathogens determined in semen using PCR and flow-through hybridization technology
    PPT Version | PDF Version
  • Brian Littlechild
    The management of violence and aggression against staff in mental health work: responding effectively through a co-production approach to issues for service users, carers, staff and agencies
    PPT Version | PDF Version
  • Tatiana Barichello
    The neuroimmunological basis of long-term behavioural sequelae in bacterial meningitis
    PPT Version | PDF Version
  • Xiao-Song He
    Distinct priming effect of live attenuated versus inactivated influenza vaccines in repeated influenza vaccination
    PPT Version | PDF Version
  • Ali Can Yilmaz
    Ali-Can-Yilmaz-Çukurova-University-Turkey-GRNN-and-MFFNN-Models-for-Energy-Equivalent-Speed-Prediction-and-Fault-Rate-Determination-of-Involvements-in-Traffic-Accidents-A-case
    PPT Version | PDF Version
  • Chin-Shyan Chen
    Antenatal Care Utilization and Infant Birthweight in Low Income Families
    PPT Version | PDF Version
  • John Agens
    Fourth year medical students required written patient care assignments reflecting awareness of use of Vitamin D in older patients at risk for falling
    PDF Version
  • Pilar Montesó Curto
    Diagnosed, Identified, Current and Complete Depression Among Patients Attending Primary Care in Southern Catalonia: Different Aspects of the Same Concept
    PPT Version | PDF Version
  • Lai-Chu See
    A preliminary finding of implementing community-based hospice palliative care
    PPT Version | PDF Version
  • Shondell Hickson
    Women and the Healthcare Law
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsonline.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsonline.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsonline.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsonline.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsonline.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsonline.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsonline.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsonline.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsonline.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsonline.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsonline.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsonline.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsonline.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsonline.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsonline.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsonline.com

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version